'Pinas, gagawing testingan ng gamot ng South Korea kontra-COVID

ni Mary Gutierrez Almirañez | April 12, 2021

Gaganapin sa ‘Pinas ang clinical trial ng bakunang EuCorVac-19 na gawa ng South Korea upang labanan ang lumalaganap na COVID-19 pandemic, ayon sa Glovax Biotech Corporation ngayong araw, Abril 12.

Ayon kay CEO Giovanni Alingog, “The reason we wanted to do a clinical trial in the Philippines is most of the companies that were given EUA (emergency use authorization) in our country have not done a clinical trial locally. The reason we wanted to trial locally is to show, for ethnicity purposes, for Filipinos, that the vaccine is also effective and safe.”

Ngayong Abril ay nakatakdang isagawa ang combined phase 1 at phase 2 trial ng EuCorVac-19.

Batay pa sa pag-aaral, nagtataglay ito ng 91% hanggang 95% na efficacy rate.

Dagdag ni Alingog, “Because of the emergency purposes or the need of vaccine, we are asking the clinical research organizations and our FDA (Food and Drug Administration) to fast-track a bit our clinical trial so we can serve the Filipino people with a quality and safe vaccine from Korea.”

Samantala, iginiit naman ni Department of Health (DOH) Secretary Francisco Duque III na nakikipagtulungan na rin ang Glovax sa Department of Science and Technology (DOST) upang makapag-develop ang ‘Pinas ng sariling bakuna kontra COVID-19.

Sa ngayon, ang may emergency use authorization (EUA) pa lang na bakuna ay ang Pfizer-BioNTech, AstraZeneca, CoronaVac ng Sinovac, at ang Sputnik V ng Gamaleya Institute.

Sputnik V COVID-19 vaccine ng Russia, aprub na sa ‘Pinas

ni Lolet Abania | March 18, 2021

Binigyan na ng emergency use authorization (EUA) ng Pilipinas ang Sputnik V COVID-19 vaccine ng Russia.

Sa late stage trial results, napag-alamang 91.6% effective ang Sputnik V, ayon kay Food and Drug Administration (FDA) Director-General Eric Domingo.

Saad pa ni Domingo, "Based on the totality of evidence available to date, including data from adequate and well-known controlled trials, it is reasonable to believe that the Gamaleya National Center of Epidemiology and Microbiology Sputnik V Gam-Cov-Vac COVID-19 vaccine may be effective to prevent COVID-19.”

Aniya pa, "The adverse events reported were mostly mild and transient, similar to common vaccine reactions. No specific safety concerns were identified.”

Samantala, aabot sa 3 million doses ng Sputnik V COVID-19 vaccine ang inorder ng Pilipinas matapos itong mabigyan ng EUA, ayon kay Vaccine Czar Secretary Carlito Galvez, Jr. ngayong Biyernes.

Saad ni Galvez, “We will have a meeting this coming Tuesday. And our initial request is for them to deliver more or less three million doses this coming April [and] May.

“We also have an ongoing negotiation with them to allow LGUs (local government units) to buy the vaccine.” Ang Sputnik V ay two-dose vaccine matapos ang tatlong linggo at ang mga edad 18 pataas lamang ang maaaring mabakunahan nito.